What is it about?
The article summarizes the recent studies with several viruses for pre-clinical testing in gastrointestinal tumors. A number of viral platforms will soon enter the clinical phase, with some of the trials already in recruiting period. This is very important as many of the gastrointestinal cancers have poor outcomes and prognosis and the need for new treatments is currently unmet.
Featured Image
Why is it important?
A number of viral platforms are being developed to reach tumor specificity, minimizing off-target adverse events. The article highlights viral construct strategies for each type of tumor and provides an overview of the next clinical phase.
Perspectives
Vector safety and specificity is a huge concern for the field of virotherapy. Many strategies have worked in pre-clinical studies, however, the clinical setting is far more challenging. The time has come to prove efficacy and on target replication, with reliable accuracy and safety.
Raquel Yokoda
Mayo Clinic
Read the Original
This page is a summary of: Oncolytic virotherapy in upper gastrointestinal tract cancers, Oncolytic Virotherapy, March 2018, Dove Medical Press,
DOI: 10.2147/ov.s161397.
You can read the full text:
Contributors
The following have contributed to this page
